poisar

Stocks · News reference

IDEXX Laboratories Raises FY2026 GAAP EPS Guidance from $14.45-$14.90 to $14.69-$14.94 vs $14.67 Est; Narrows FY2026 Sales Guidance from $4.675B-$4.760B to $4.700B-$4.745B vs $4.711B Est

Aug 4, 2026, 10:31 AMBenzinga Newsdesk

IDEXX Laboratories (NASDAQ:IDXX) raises FY2026 GAAP EPS guidance from $14.45-$14.90 to $14.69-$14.94 vs $14.67 analyst estimate. Narrows FY2026 sales outlook from $4.675 billion-$4.760 billion to $4.700 billion-$4.745

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

IDXX
Source
benzinga
Observed
Aug 4, 2026, 10:31 AM
Checked
Aug 4, 2026, 10:31 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 25, 2026, 6:53 PMBcc Research

    Global Veterinary Medical Devices Market to Reach $9.1 Billion by 2030, Driven by Rising Pet Ownership and Technological Innovation in Animal Healthcare

    The global veterinary medical devices market is projected to grow from $6.5 billion in 2024 to $9.1 billion by 2030 at a 6.1% CAGR, driven by pet humanization trends, expanding pet insurance coverage, and AI-enabled diagnostic innovations. North America dominates with 55.9% market share, while emerging markets present long-term growth opportunities.

    Read original at globenewswire-inc
    IDXXZTSMDT